Trending Now

Nivesh.live

Invest Wisely, Grow Steadily

Menu
Search
Headline
10 reasons why gold is a good buy in 2025 – CNBC TV18
10 reasons why gold is a good buy in 2025 – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday

Tag: Prepfar funding freeze

News
Sarvesh Gautam

Cipla to exceed FY25 guidance, sees minimal impact from PEPFAR funding freeze – CNBC TV18

[ad_1] Cipla Ltd. has expressed optimism about exceeding its FY25 guidance, supported by strong operational performance and a focused strategy. Company Value Change %Change The company stated that supply challenges related to Lanreotide, a crucial product, are expected to ease from Q1 FY26, paving the way for improved output and consistent supply. The management also […]

Back To Top
Translate »